Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Malignant Pleural Mesothelioma Condition: Unresectable or not candidates for curative surgery |
Dose: Intravenous – 500 mg/m² Frequency: once every 21-day cycle on Day 1 Note: Administer over 10 minutes; administer cisplatin (75 mg/m² intravenous over 2 hours) 30 minutes after end of pemetrexed infusion. |
|
Indication: Nonsquamous Non-Small Cell Lung Carcinoma Condition: Initial treatment |
Dose: Intravenous – 500 mg/m² Frequency: once every 21-day cycle on Day 1 Note: Administered with cisplatin (75 mg/m² intravenous over 2 hours) 30 minutes after end of pemetrexed infusion. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: Tablet – Safety and efficacy not established Note: Safety and efficacy not established |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment: Creatinine Clearance (ml/min) less than 45 |
Dose: Usage is not recommended. Note: Usage is not recommended. |
Administration
- For IV infusion only
- Infuse over 10 minutes
Side Effect
- Nausea (84%)
- Fatigue (80%)
- Pulmonary dyspnea (66%)
- Neutropenia (58%)
- Vomiting (58%)
- Leukopenia (55%)
- Constipation (44%)
- Chest pain (40%)
- Anorexia (35%)
- Anemia (33%)
- Pharyngitis (28%)
- Stomatitis (28%)
- Thrombocytopenia (27%)
- Diarrhea without colostomy (26%)
- Rash/desquamation (22%)
- Fever (17%)
- Neuropathy/sensory (17%)
- Creatinine elevation (16%)
- Mood alteration/depression (14%)
- Infection without neutropenia (11%)
- Dehydration
- thrombosis/embolism (7%)
- Dysphagia/esophagitis/odynophagia (6%)
- Infection with Grade 3 or Grade 4 neutropenia (6%)
- Neutropenia-other (3%)
- Allergic reaction/hypersensitivity (2%)
- Renal failure (2%)
- Febrile neutropenia (1%)
- Esophagitis
- Arrhythmia
- Motor neuropathy
- Febrile neutropenia
- Erythema multiforme
- Acute renal failure
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
NSAIDs (Ibuprofen, Naproxen, Diclofenac, Celecoxib, Meloxicam, Indomethacin, Piroxicam, Ketorolac), aspirin
|
High doses may reduce the elimination of pemetrexed; avoid usage 2 days (5 days for longer-acting NSAIDs) before, during and 2 days after treatment in patients with impaired renal function
|
|
SSRIs, acetylCholinesterase Inhibitors (Neostigmine, Pyridostigmine, Donepezil), aripiprazole, ziprasidone
|
Additive GI side effects
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Data not available
|
Data not available
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F)
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.